What is Neuland Laboratories Limited's (NEULANDLAB.NS) StockRank?

MoatMap's StockRank for Neuland Laboratories Limited (NEULANDLAB.NS) is 64/100, with a Hold signal. This is a composite score combining Quality (61), Value (11), and Momentum (86) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Neuland Laboratories Limited have an economic moat?

Neuland Laboratories Limited (NEULANDLAB.NS) has a Quality factor score of 61/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Neuland Laboratories Limited a buy, hold, or sell?

MoatMap's current signal for Neuland Laboratories Limited (NEULANDLAB.NS) is Hold, based on a StockRank of 64/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Neuland Laboratories Limited in?

Neuland Laboratories Limited (NEULANDLAB.NS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (India).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NEULANDLAB.NS

HoldPremium Grower

Neuland Laboratories Limited · Healthcare · India · $3.2B · Avg Vol: $22M/d

StockRank

Get insider-trade alerts

P/E (TTM)

59.7x

ROE

19.4%

D/E

0.2x

Dividend %

0.1%

COMPANY DESCRIPTION

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services.

FINANCIAL SUMMARY (INR)

Year	2023	2024	2025	2026	CAGR	TTM	2027E	2028E	Fwd CAGR
Revenue	11.6B	15.2B	14.3B	19.3B	18.5%	6.1B	24.4B	29.3B	23.1%
EPS (INR)	127.45	233.89	202.74	283.71	30.6%	390.05	369.49	490.83	31.5%
Shares	12.8M	12.8M	12.8M	12.8M	0.0%	12.8M	—	—	—
Debt	1.3B	953.9M	1.6B	3.0B	32.9%	3.0B	—	—	—
Equity	9.9B	12.8B	15.2B	18.7B	23.5%	—	—	—	—
Op CF	2.4B	2.6B	3.2B	3.5B	13.5%	3.5B	—	—	—
Inv CF	-615.0M	-1.5B	-3.0B	-4.2B	—	—	—	—	—
Fin CF	-1.4B	-692.8M	249.6M	209.8M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+17.8%

SMA 50SMA 200

$243.06

RSI (14)

49.0

52W High

$253.85

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

31.3%96.7

ROE

19.4%87.8

GP/Assets

7.3%21.3

Op. Margin

30.6%92.1

FCF/Assets

-1.7%41.1

Piotroski

668.8

Int. Cover

26.4x73.5

D/E Ratio

0.16x54.2

Current Ratio

1.42x24.2

Value

P/E (TTM)

59.7x17.5

EV/EBITDA

580.5x0.8

P/FCF

—N/A

P/B

15.9x7.0

P/S

49.1x9.7

Div Yield

0.1%3.4

Momentum

52W High %

96%95.1

RS 6M

89%95.7

SMA 50/200

1.27x91.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+26%39.0

Q Growth

962%98.4

FUNDAMENTALS

Market Cap

$3.2B

P/E (Forward)

47.3x

Gross Margin

35.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NEULANDLAB.NS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NEULANDLAB.NS	Neuland Laboratories Limited(you)	$3.2B	64	Hold
PPLPHARMA.NS	Piramal Pharma Limited	$3.2B	58	Hold
WOCKPHARMA.NS	Wockhardt Limited	$3.8B	54	Hold
SHILPAMED.NS	Shilpa Medicare Limited	$2.0B	69	Buy
JUBLPHARMA.NS	Jubilant Pharmova Limited	$1.7B	60	Hold
ERIS.NS	Eris Lifesciences Limited	$1.9B	56	Hold
ALKEM.NS	Alkem Laboratories Limited	$6.5B	69	Buy
EMCURE.NS	Emcure Pharmaceuticals Limited	$3.9B	81	Strong Buy
AJANTPHARM.NS	Ajanta Pharma Limited	$4.7B	79	Buy
NATCOPHARM.NS	NATCO Pharma Limited	$1.6B	72	Buy

Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%

Neuland Laboratories Limited (NEULANDLAB.NS): Stock Score Summary

Neuland Laboratories Limited (NEULANDLAB.NS) has a MoatMap StockRank of 64/100 based on Quality (61/100), Value (11/100), and Momentum (86/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$243.06
Market Cap	$3.2B
P/E (TTM)	59.67
P/E (Forward)	47.26
Price/Book	15.88
Return on Equity	19.4%
Return on Invested Capital	31.3%
Debt/Equity	0.16x
Gross Margin	35.2%
Operating Margin	30.6%
Revenue Growth	119.2%
Dividend Yield	0.1%
Free Cash Flow	$-5M

Neuland Laboratories Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (India).

Frequently Asked Questions

What is Neuland Laboratories Limited’s (NEULANDLAB.NS) StockRank?: MoatMap’s StockRank for Neuland Laboratories Limited (NEULANDLAB.NS) is 64/100, with a Hold signal. It is a composite of Quality (61), Value (11), and Momentum (86) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Neuland Laboratories Limited have an economic moat?: Neuland Laboratories Limited (NEULANDLAB.NS) has a Quality factor score of 61/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Neuland Laboratories Limited a buy, hold, or sell?: MoatMap’s current signal for Neuland Laboratories Limited (NEULANDLAB.NS) is Hold, based on a StockRank of 64/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Neuland Laboratories Limited in?: Neuland Laboratories Limited (NEULANDLAB.NS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (India).